<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146416</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1642</org_study_id>
    <nct_id>NCT03146416</nct_id>
  </id_info>
  <brief_title>Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the safety and tolerability of subcutaneous
      (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">June 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to week 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>Baseline up to week 31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of evinacumab for geometric means of maximum (or peak) serum concentration (Cmax)</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of evinacumab for geometric means of Area under the curve (AUC) computed from time zero to the last measurable concentration (AUClast)</measure>
    <time_frame>Up to Week 31</time_frame>
    <description>single dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of evinacumab for geometric means of AUC computed from time zero to the end of a dosing interval (AUCtau)</measure>
    <time_frame>Up to Week 31</time_frame>
    <description>following the first dose for the multiple dose cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Japanese versus Caucasian populations for geometric means of Cmax</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Japanese versus Caucasian populations for geometric means of AUClast</measure>
    <time_frame>Up to Week 31</time_frame>
    <description>single dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Japanese versus Caucasian populations for geometric means of AUCtau</measure>
    <time_frame>Up to Week 31</time_frame>
    <description>following the first dose for the multiple dose cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the Pharmacodynamic (PD) variable: Low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: Total cholesterol</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: High-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: Triglycerides</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: non-HDL-C</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: lipoprotein a [Lp(a)]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: apolipoprotein B [ApoB]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: apolipoprotein A1 [ApoA1]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: apolipoprotein C3 [ApoC3]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: high-sensitivity C-reactive protein [hs-CRP]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline over time in the PD variable: Total Angiopoietin-like 3 (ANGPTL3)</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: LDL-C</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: Total cholesterol</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: HDL-C</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: Triglycerides</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: non-HDL-C</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: lipoprotein a [Lp(a)]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: apolipoprotein B [ApoB]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: apolipoprotein A1 [ApoA1]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: apolipoprotein C3 [ApoC3]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: high-sensitivity C-reactive protein [hs-CRP]</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline over time in the PD variable: Total (ANGPTL3)</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-evinacumab antibodies</measure>
    <time_frame>Up to Week 31</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evinacumab SC or placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose regimen: evinacumab IV or placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose regimen: evinacumab IV or placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evinacumab or placebo SC every week (QW) x 8 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evinacumab or placebo SC x 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evinacumab</intervention_name>
    <description>SC or IV administration of Evinacumab</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>REGN1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male or female Japanese and Caucasian volunteers ≥18 and ≤55 years of age at
             the screening visit.

          -  Japanese subjects must:

               1. Be first generation Japanese, defined as born in Japan and both biologic parents
                  are ethnic Japanese

               2. Have maintained a Japanese lifestyle that has not significantly changed since
                  leaving Japan, including having access to Japanese food and adhering to a
                  Japanese diet.

          -  Caucasian subjects must be Caucasian of European or Latin American descent

          -  Modest elevations in LDL-C (≥100 mg/dL, but &lt;160 mg/dL)

        Key Exclusion Criteria:

          -  Significant concomitant illness

          -  Known allergy or sensitivity to monoclonal antibodies (mAbs)

          -  Previous exposure to anti-ANGPTL3 antibody

          -  Body mass index (BMI) &gt;35 kg/m2 at the screening visit

        Note: Other protocol-defined inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

